A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to produce defence proteins, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from birth
- Protection possible with two-week gap before early delivery
- Vaccination in the third trimester still offers significant protection for infants
Strong evidence from current research
The performance of the RSV vaccine administered during pregnancy has been established through a comprehensive study carried out throughout England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s real-world impact. The study’s results have been validated by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study gives healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across diverse populations and circumstances.
The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This marked difference highlights the vaccine’s essential role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured actual clinical results rather than experimental conditions, providing tangible evidence of how the vaccine functions when administered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed properly. Parents commonly see their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their compromised lungs. Whilst most newborns get better with clinical support, a modest yet notable number die from RSV-related complications each year, making immunisation programmes a vital health service imperative for defending the youngest and most at-risk people in our communities.
- RSV causes inflammation in lungs, causing severe breathing difficulties in babies
- Approximately half of newborns catch the virus in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- More than 20,000 UK infants require serious hospital care for RSV annually
- Small numbers of babies succumb to RSV complications each year in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have stressed the importance of pregnant women receiving their jab at the optimal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns receive the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides approximately 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies through the placenta.
The guidance from public health bodies stays clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences reflect variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts deploying varied communication campaigns to engage with pregnant women
- Geographic variations in vaccination coverage levels throughout England require targeted improvement
- Local healthcare systems tailoring initiatives to align with community needs and circumstances
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness provides real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants protected against severe infection. Parents no more face the upsetting situation of watching their newborns struggle for breath or struggle to eat, symptoms that mark serious RSV disease. The vaccine has markedly changed the landscape of neonatal breathing health, providing expectant mothers a preventative option to safeguard their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection caused profound brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab underscores the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to pregnant women navigating their third trimester, changing what was once an inevitable seasonal threat into a manageable health risk.